RhumbLine Advisers
OMED

RhumbLine Advisers’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

RhumbLine Advisers’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,417
Closed -$206K – 3044
2017
Q1 		$206K Buy
22,417
+2,179
+11% +$19.1K ﹤0.01% 2646
2016
Q4 		$156K Buy
20,238
+1,718
+9% +$15.8K ﹤0.01% 2733
2016
Q3 		$212K Buy
18,520
+1,625
+10% +$18.9K ﹤0.01% 2653
2016
Q2 		$208K Buy
16,895
+425
+3% +$5.16K ﹤0.01% 2723
2016
Q1 		$167K Buy
16,470
+165
+1% +$1.94K ﹤0.01% 2792
2015
Q4 		$368K Buy
16,305
+1,435
+10% +$29.4K ﹤0.01% 2450
2015
Q3 		$247K Buy
14,870
+575
+4% +$11.5K ﹤0.01% 2667
2015
Q2 		$322K Buy
14,295
+2,465
+21% +$60.8K ﹤0.01% 2613
2015
Q1 		$305K Buy
11,830
+1,600
+16% +$40.6K ﹤0.01% 2603
2014
Q4 		$223K Buy
+10,230
New +$210K ﹤0.01% 2747
2014
Q3 		– Sell
-9,930
Closed -$231K – 3031
2014
Q2 		$231K Buy
+9,930
New +$245K ﹤0.01% 2751

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's OMED Position: Q2 2017 in Review

RhumbLine Advisers sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 22,417 shares — an estimated $206K sold.

RhumbLine Advisers first reported a position in OMED in Q2 2014 and held it in 11 quarters. The position peaked at $368K in Q4 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • RhumbLine Advisers reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • RhumbLine Advisers sold 22,417 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $206K.
  • RhumbLine Advisers first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2014 and held it in 11 quarters.
  • RhumbLine Advisers's OncoMed Pharmaceuticals, Inc. position peaked at $368K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.